Quintessence Biosciences, Inc. Presents Efficacy Data for Next Generation Evade™ Ribonucleases at Cancer Meeting
Published: Oct 23, 2008
QBI-139 is a potent anticancer agent based on the EVade™ Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new cancer drug target, with analogs of the human pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown an exceptional safety profile and outstanding tumor growth inhibition in vivo against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. Of approximately 40 different EVade™ Ribonucleases tested to date, QBI-139 had the best therapeutic index as well as the broadest efficacy in multiple tumor lines.
Quintessence projects a Phase 1 clinical trial for QBI-139 will begin in the upcoming months, subject to U.S. Food and Drug Administration (FDA) review.
“The success of the next generation Evade™ Ribonuclease conjugates significantly broadens the potential impact of our drug candidates,” said Quintessence Biosciences CEO Ralph Kauten. “Conjugates of proteins with water soluble polymers have historically provided safer and more effective products relative to the unconjugated proteins.”
About Quintessence Biosciences, Inc.
Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is anticipated to enter a Phase 1 clinical trial soon. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.
About the International Conference on Molecular Targets and Cancer Therapeutics
Three of the world’s leading cancer organizations:
The European Organization for Research and Treatment of Cancer
The USA’s National Cancer Institute
The American Association for Cancer Research
will join forces in Geneva Switzerland from October 21-24, 2008 to provide a platform for presenting the recent advances in the early development of promising new compounds in different stages of pre-clinical and clinical research to around 2,200 international experts in the field.